Aptamers are single-stranded DNA or RNA molecules with unique 3D structures that allow for specific binding to a wide variety of ions and molecules. Due to their unique properties, aptamers have been ...
Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...
RB-164 employs a novel Fc-silenced monoclonal antibody targeting ROR-1, site specific conjugation to deliver a homogeneous Drug-to-Antibody distribution and prevent retro-Michael elimination (high ...
Questions are answered by experts at the Oregon Health Authority, other state agencies or community partners. Questions and ...
Solid tumors are difficult to treat due to their heterogeneity and limited blood supply, which restrict the effective ...
Investing News Network on MSN11d
What is In-Licensing?When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is ...
Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
Pennsylvania’s school immunization requirements can be found in 28 Pa.CODE CH.23 (school immunization). For more information, ...
Zilovertamab vedotin is Merck’s investigational antibody-drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1). Global recruitment of the waveLINE-010 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback